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ABSTRACT
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospe-
mifene 60mg (SenshioVR ) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy
(VVA). A literature search was carried out of clinical efficacy/safety trials of local vaginal estrogens in
VVA approved in Europe. For efficacy comparison, studies had to be placebo-controlled and of 12
weeks’ duration. For safety comparison, studies had to be 40 weeks’ duration. Efficacy endpoints
were the difference between active and placebo in change from baseline to week 12 for symptoms,
vaginal pH, and maturation value (MV). Safety endpoints were endometrial safety, breast safety, throm-
bosis, and adverse events. The 12-week improvement over placebo in symptom score was not different
for ospemifene 60mg and 17b-estradiol 10lg and for ospemifene 60mg and estriol gel. After 12
weeks, the percentages with vaginal pH <5.0 and <5.5 were better for ospemifene 60mg than 10lg
17b-estradiol. Week-12pH changes were comparable with estriol pessaries or gel and ospemifene
60mg. The 12-week MV improvements over placebo were similar or better with ospemifene 60mg
compared with 10lg 17b-estradiol and with estriol pessaries or gel. There was no increased vaginal
bleeding, endometrial hyperplasia, or carcinoma (including breast cancer) relative to placebo and no
signal for increased risk of venous thromboembolism with ospemifene 60mg or 10lg 17b-estradiol,
but the confidence intervals for both products do not exclude an increased risk. This historical indirect
comparison suggests that ospemifene 60mg has an efficacy, safety, and tolerability profile comparable
to or better than local vaginal estrogens in the treatment of VVA.
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Introduction
Vulvar and vaginal atrophy (VVA) is a chronic and progressive
medical condition that develops because of the decline of
estrogen levels1,2. Symptoms, including vaginal dryness, irrita-
tion, soreness, and dyspareunia plus urinary frequency,
urgency, and urge incontinence, usually persist or worsen in
the absence of treatment3. Approximately 50% of postmeno-
pausal women suffer from VVA symptoms4. Local vaginal
estrogens represent the current standard of care for treat-
ment of symptomatic VVA and are effective in alleviating
symptoms of moderate-to-severe VVA5–7. However, there are
some significant barriers to treatment, including lack of
knowledge about VVA, reluctance to discuss symptoms with
health-care professionals, safety concerns, contraindications
to estrogen use and inconvenience8,9.
The non-estrogen selective estrogen receptor modulator
(SERM) ospemifene (SenshioVR ) provides a new oral therapy
option for postmenopausal women with moderate or severe
symptomatic VVA who are not candidates for local estro-
gens7,10. Ospemifene acts by exerting a tissue-specific effect,
including an estrogen agonist effect on the vaginal
epithelium11,12. The efficacy and safety of ospemifene were
established in 30 clinical trials, with 2471 subjects exposed to
ospemifene. These studies formed the basis for the EU
approval of ospemifene for the treatment of moderate-to-
severe symptomatic VVA in postmenopausal women who are
not candidates for local vaginal estrogen therapy10.
Direct comparisons between oral ospemifene and locally
delivered estrogens have not been performed and would be
technically and scientifically challenging.
In the absence of direct (head-to-head) comparisons in
randomized clinical trials and at the request of EU regulatory
authorities, an indirect historical comparison was performed
of ospemifene vs. local estrogens that are currently available
for VVA treatment in Europe.
Methods
Identification and selection of studies
A literature search of all articles published up to 25 October
2012 was conducted using PubMed to identify publications
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of clinical trials of local vaginal estrogens for the treatment
of VVA. Additional searches were conducted using Cochrane
Reviews and www.clinicaltrials.gov.
Studies on the efficacy of local estrogens were selected
using the following criteria: (1) the study evaluated mono-
therapy and was placebo-controlled; (2) relevant endpoints
were evaluated at 12 weeks; (3) the formulation was available
on the market in Europe.
For the long-term safety evaluation, local estrogen studies
were only included if the duration was 40 weeks and if the
formulation was available in Europe. Trials on systemic hor-
mones or studies on indications other than vaginal atrophy
and open-label data were excluded.
Endpoints
The efficacy endpoints considered were symptoms, vaginal
pH, and maturation value (MV). The safety endpoints consid-
ered were endometrial safety (including vaginal bleeding),
breast safety, venous thromboembolism (VTE), and most
common adverse events (AEs).
Statistical analyses
Comparisons between local estrogen and ospemifene data
were conducted for the three efficacy outcomes of symp-
toms, pH, and MV, where available. Since baseline data, as
well as the study populations, were somewhat different, the
comparison is corrected for baseline (difference from base-
line) and, as much as possible, for differences between treat-
ment groups (difference in change from baseline between
active and placebo arms). All changes/effects discussed are
relative to placebo (i.e. the data were normalized to the pla-
cebo population to show the effect of the drug regardless of
the population/study differences). If the differences from pla-
cebo are different between different products, the direction
of the difference has been indicated.
For each endpoint, both mean 12-week changes within
each treatment arm and 12-week changes relative to placebo
were estimated (mean difference between arms¼mean in
active arm – mean in placebo arm). Two-sided 95% confi-
dence intervals (CIs) for 12-week differences between active
and placebo arms were estimated assuming normally distrib-
uted data.
For the comparison of safety, incidence proportions were
calculated by dividing the number of events by the number
of observed cases. Data from different ospemifene studies
were pooled. Data from studies on local estrogens could only
be pooled for the VTE data.
Results of the indirect comparison
Study identification
Efficacy analysis
Out of 88 clinical studies using a local estrogen as an active
comparator, 21 studies were placebo-controlled, including 19
studies with unique data. Of these, 15 were excluded from
the efficacy analysis for the reasons listed in Table S1
(Supplementary Material, see http://dx.doi.org/10.1080/
13697137.2017.1284780), e.g. the populations or endpoints
were not comparable or the active component is no longer
available in Europe. Of the remaining studies, two assessed
10 lg 17b-estradiol (VagifemVR )13,14. Details of these studies
are summarized in Table 1. 17b-Estradiol 25 lg, one of the
treatment groups studied by Bachmann13, has been largely
withdrawn from the European market and was not included
in the efficacy evaluation.
Low-dose estriol vaginal ovulae and estriol gel are now
approved in some countries and two studies, one assessing
estriol pessaries and one estriol gel, are also included15,16.
Eight 60mg ospemifene phase 2/3 studies were identified.
Two studies were excluded as they were in healthy post-
menopausal volunteers, one because it was only of 6 weeks’
duration, and two because they were long-term extension
phases with no efficacy data. Ospemifene 60mg, 12-week,
placebo-controlled efficacy data for comparison were avail-
able from the three pivotal trials in women with VVA
(Studies 15-5031017, 15-5071818, and 15-50821 for the dys-
pareunia arm19 and for the dryness arm20) (Table 1).
Safety analysis
Of the 88 clinical studies on local estrogens, 14 studies had a
duration 40 weeks. Three of these were excluded from the
safety analysis because they reported data for an estrogen
that is not available in Europe and one small study (n¼ 68)
because the full text article could not be located (published
in Czech). The ten remaining studies included five on 10 lg
17b-estradiol and four studies investigated an estradiol ring
(Table 2). One of the 10 lg 17b-estradiol studies26 reported
the results of a pooled analysis of data from two studies14,27.
For Weisberg23, only data from the Estring arm were included
as 25 lg 17b-estradiol is being withdrawn and is no longer
available in many EU countries. Data from Bachmann13 were
excluded because patients were switched from 10 lg 17b-
estradiol to 25 lg 17b-estradiol after 12 weeks’ treatment.
Ospemifene 60mg long-term safety data came from the
pivotal 52-week, double-blind, placebo-controlled trial (Study
15-5071818) and the blinded 40-week extension from one of
the pivotal 12-week, double-blind, placebo-controlled trials
(Study 15-50310x29). As the authors had access to the study
reports of the ospemifene studies, the safety data from the
15-50310x study include the safety data from the preceding
15-50310 study for those women who continued in Study
15-50310x, thus representing 52 weeks of observation for
safety reporting. In order to allow comparison with the publi-
cations of local estrogens, some of the other ospemifene
data were also taken from the ospemifene clinical trial
database.
Efficacy comparison
There were differences in the study designs and patient
baseline characteristics between the local estrogen and ospe-
mifene trials (e.g. age, time since menopause, and baseline
MV) (Table 3). At enrolment, all of the women in the
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CLIMACTERIC 3
ospemifene trials and the Simon 2008 10 lg 17b-estradiol
study had a pH >514, whereas approximately 11% of women
had a lower pH value in the Bachmann 10 lg 17b-estradiol
study13. Also in the estriol studies, some women (number
unknown) had a pH <5 (range 4.5–7.0 at baseline for
Griesser15, 6.4 ± 1.4 (mean± SD) for Cano16). MVs at baseline
varied across studies, ranging from 9.3 to 47.5, despite the
fact that the inclusion criteria in most studies specified that
superficial cells had to be 5%.
In the two estriol studies, only observed case data are
published so, for comparison, observed case data for 60mg
ospemifene are also provided.
Composite symptom scores, including the most bother-
some symptom
A composite score, based on a four-point severity scale
(none, mild, moderate, severe) for the most bothersome
symptom (MBS) of VVA (which included vaginal dryness, dys-
pareunia, vaginal soreness, vaginal and/or vulvar irritation/
itching, dysuria or vaginal bleeding associated with sexual
activity) was used to compare 60mg ospemifene with 10 lg
17b-estradiol14. The improvement at week 12 relative to pla-
cebo was not different for ospemifene and that reported for
10 lg 17b-estradiol (Figure 1). The improvement relative to
placebo could not be calculated for the Bachmann study13,
but the magnitude of improvement was similar to that in the
Simon 2008 study14. The symptom score for estriol, as
reported by Griesser15, could not be compared due to a dif-
ferent assessment method (visual analog scale). A global
symptom score, based on a composite of the intensity scores
of all symptoms of vaginal dryness, dyspareunia, pruritus,
burning, and dysuria, was used in the estriol gel study16, so
ospemifene data were recalculated using the same definition.
The magnitude in placebo-subtracted improvement from
baseline to week 12 was comparable for estriol gel 0.005%
(1.07) and 60mg ospemifene (1.02–1.27).
Data for the percentage of subjects cured or improved of
their symptom of vaginal dryness and dyspareunia are
given in Table 4. The improvement with ospemifene relative
to placebo is at least comparable to that with estriol 0.005%
gel16.
Table 2. Local estrogen studies with a duration 40 weeks.
Reference Country Duration Active arm
Comparator
arm Total (n) Patient population
Hysterectomized
women included
Henriksson et al.
199621
Sweden 48 weeks Estring None 136 >2 years postmenopause,
vaginal atrophy symp-
toms, signs of atrophic
vaginal mucosa
Yes
Naessen &
Rodriquez-
Macias 200222
Sweden 12 months Estring Untreated
controls
60 Women 60 years of age Yes
Weisberg et al.
200523
Australia 48 weeks Estring 25 lg
17b-estradiol
185 >2 years postmenopause,
VVA symptoms or
signs, endometrium
5mm, negative PCT
No
Gerbaldo et al.
199124
Italy 52 weeks Estriol (Colpogyn) None 23 Postmenopause, urogenital atrophy complaints
Iosif 199225 Sweden 8–10 years Estriol (Organon) None 48 Postmenopause, vaginal atrophy/urinary incon-
tinence/recurrent UTI
Simon et al. 201026 Canada, US, Czech
Republic, Denmark,
Sweden, Finland,
Norway, France,
Hungary
52 weeks 10 lg 17b-estradiol Placebo 541 >2 years postmenopause,
> 45 years, urogenital
symptoms (1 moder-
ate-severe), serum lev-
els criteria, endometrial
criteria
No
Ulrich et al. 201027,a 40 sites in 7 European
countries (Czech
Republic, Denmark,
Finland, France,
Hungary, Norway,
Sweden)
52 weeks 10 lg 17b-estradiol None 336 >2 years postmenopause,
45 years, urogenital
symptoms (1 moder-
ate-severe), serum lev-
els criteria, endometrial
criteria
No
Smith et al. 199328 Sweden 48 weeks Estradiol ring None 222 >2 years postmenopause No
Bachmann et al.
200813
US 52 weeks 10/25 lg
17b-estradiol
Placebo 230 >1 year postmenopause,
>45 years, moderate-
severe vaginal dryness
& soreness, serum cri-
teria, endometrial
criteria
Yes
Simon et al.
200814,a
US, Canada 52 weeks 10 lg 17b-estradiol Placebo 205 >2 years postmenopause,
45 years, 3 uro-
genital symptoms (1
moderate-severe),
serum levels criteria,
endometrial criteria
No
a, Endometrial safety data reported in Simon et al. 201026
PCT, progesterone challenge test; UTI, urinary tract infection
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Vaginal pH Value
In the Bachmann 10 lg 17b-estradiol study13, only data on
the proportion of women with a pH <5 were reported. The
percentages of women achieving a vaginal pH <5 with ospe-
mifene relative to placebo and 10 lg 17b-estradiol vs. pla-
cebo are shown in Figure 2a.
In the Simon 2008 study14, only data on the proportion of
women with a pH <5.5 were reported. The percentages of
women achieving a vaginal pH <5.5 with ospemifene relative
to placebo and 10 lg 17b-estradiol vs. placebo are shown in
Figure 2b.
In the two estriol studies, only change from baseline pH
(observed case data) was reported. The placebo-subtracted
mean changes from baseline pH with both doses of estriol
pessary and with estriol gel were not different to those
observed with 60mg ospemifene (Figure 2c).
Maturation value
The MV was derived from the maturation index according to
the formula: MV¼ 1percentage of superficial cellsþ 0.5
percentage of intermediate cells.
The improvements in MV vs. placebo over 12 weeks for
women treated with 60mg ospemifene and 10 lg 17b-estra-
diol in the Simon 2008 study14 (last observation carried for-
ward), estriol pessary/gel in the Griesser15 and Cano16 studies
(observed case data), and 10 lg 17b-estradiol in the
Bachmann study13 are shown in Figure 3a and b.
Safety comparison
Vaginal bleeding
Three local estrogen studies21,23,28 reported data on vaginal
bleeding, although they have limited comparability to ospe-
mifene data (open label or inspection-only). The rate of vagi-
nal bleeding per 1000 women-years was 21.72 (95% CI
10.41–39.94) for 60mg ospemifene and 26.34 (95% CI
8.55–61.46) for placebo. There is no increase in the rate of
vaginal bleeding for ospemifene compared with placebo10.
Endometrial thickness and biopsy
Endometrial thickness after 1 year was reported in three local
estrogen studies (Table 5). All showed that mean endometrial
thickness remained unchanged over 1 year of treatment,
whereas there was a small increase over 52 weeks in mean
endometrial thickness of women treated with 60mg ospemi-
fene (Table 5).
Endometrial biopsies of women at 12 months were
reported in two studies on 10 lg 17b-estradiol26 (see Table
S2, Supplementary Material, http://dx.doi.org/10.1080/
13697137.2017.1284780). The 1-year histology data for both
products were not significantly different from the baseline
data (Table S2, Supplementary Material, http://dx.doi.org/10.
1080/13697137.2017.1284780).
There was one event of carcinoma and one complex
hyperplasia without atypia with 10 lg 17b-estradiol in the
Simon 2010 study26, but no carcinoma with 60mgTa
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ospemifene in any of the studies (Table S2, Supplementary
Material, http://dx.doi.org/10.1080/13697137.2017.1284780).
Breast safety
There were no cases of breast cancer in the ospemifene
population, but one case of carcinoma-in-situ in the placebo
group30. Breast cancer risk estimates for estrogens were
drawn from systemic exposure and it is not known how
these apply to local treatments. None of the local estrogen
studies reported comparable data on breast safety. A history
of breast cancer is a contraindication for all local estrogens31,
but once (adjuvant) treatment has been completed, women
with a history of breast cancer can use ospemifene10.
Venous thromboembolism
Hormone replacement therapy (HRT) is associated with a
1.3–3-fold risk of developing VTE, i.e. deep vein thrombosis
or pulmonary embolism. The occurrence of such an event is
more likely in the first year of HRT than later31.
There were no cases of VTE in the 10 lg 17b-estradiol clin-
ical database, but the 95% CI provides an indication of the
uncertainty due to the small size of the database (upper CIs
were calculated for risk using Poisson distribution and test-
based methods32). The incidence of VTE for ospemifene
(3.65/1000 women-years) was comparable to the incidence
in the placebo population (3.66/1000 women-years)10.
Despite the absence of any VTEs in the 10 lg 17b-estradiol
database, the CIs for the incidence proportion (IP, in %) of
VTE for 10 lg 17b-estradiol (95% CI 0–1.23) were not different
to the CIs for the IP of VTE for 60mg ospemifene (95% CI
0.020–0.581).
Adverse events
The 52-week placebo-controlled study with 10 lg 17b-estra-
diol14 can be considered the most comprehensive for com-
parison of AEs, while reports from open-label studies may
not be comparable. Most of the other published local estro-
gen studies either did not report on AEs or reported AEs
very selectively.
Hot flushes Although hot flushes have been observed with
a higher frequency in patients treated with 10 lg 17b-estra-
diol compared with placebo, the incidence remains below
1%31. As with other SERMs, there was a trend towards a
higher incidence of hot flushes reported as an AE in women
treated with 60mg ospemifene over 52 weeks compared
with placebo18.
Vaginal candidiasis For both ospemifene and 10 lg 17b-
estradiol, there was a comparable higher incidence of vaginal
candidiasis in the active arms than in the placebo arms: 8.3%
vs. 2.9% for 10 lg 17b-estradiol and placebo, respectively14
compared with 7.7% vs. 1.6% for 60mg ospemifene and pla-
cebo, respectively18.
Vaginal discharge The incidences of vaginal discharge in
the 60mg ospemifene and placebo groups were 5.5% and
0%, respectively, in the Goldstein study18 and 1.4% and 0%,
respectively, in study 15-50310/15-50310x. Vaginal hemor-
rhage, vaginal discharge, or discomfort have been reported
in up to 10% of patients using 10 lg 17b-estradiol31,33.
Muscle spasms Muscle spasm is a side-effect that has been
observed with other SERMs on the market34–36. In study 15-
50310/15-50310x, the incidence of muscle spasm was 1.4% in
the 60mg ospemifene group and 0% in the placebo group;
the corresponding values in study 15-50718 were 8.5% and
6.5%, respectively. The majority of muscle spasms in the
ospemifene phase 2/3 study program were reported as leg
cramps (50/68, 74%) with 96% reported as mild (n¼ 40) or
moderate (n¼ 25). No data on muscle spasms could be
found for local estrogens.
Headache One local estrogen study reported data on
headache, but was not placebo-controlled27. The incidence of
headache was lower for 60mg ospemifene vs. placebo in
studies 15-50310/15-50310x and 15-5071818. In the list of AEs
observed with a higher frequency in patients treated with
10 lg 17b-estradiol compared with placebo, it is reported
that headache occurred in 1–10% of subjects using 10 lg
17b-estradiol31,33.
Discussion
Due to the absence of a direct comparison between ospemi-
fene and local estrogens, we performed an historical indirect
comparison of the efficacy and safety of ospemifene with
local estrogens in the treatment of VVA. We found that the
magnitudes of changes relative to placebo in both subjective
and objective efficacy measures were similar to or greater
with 60mg ospemifene than those observed with 10 lg 17b-
estradiol or estriol. The improvements in placebo-subtracted
composite symptom scores at week 12 were similar for ospe-
mifene vs. 10 lg 17b-estradiol (MBS) and for ospemifene vs.
estriol gel 0.005%. The percentages of women achieving a
pH <5 or <5.5 with 60mg ospemifene relative to placebo
Treatment difference (change from baseline in composite MBS)
Vagifem 10 µg (Simon et al 2008)
Ospemifene 60 mg (Study 50310)
Ospemifene 60 mg (Study 50821)
−0.52−0.57 −0.47 −0.42 −0.37 −0.32 −0.27 −0.22 −0.17 −0.12 −0.07
Figure 1. Difference between active arm and placebo in composite most bothersome symptom (MBS) at week 12. Score based on severity of the most bothersome
symptom: none¼ 0, mild¼ 1, moderate¼ 2 and severe¼ 3. A decrease in score means improvement in symptom severity.
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Table 4. Improved or cured proportions and relative proportions for vaginal dryness and dyspareunia at 12 weeks, observed cases.
Cano et al. 201216 Study15-50310 Study 15-50821
Placebo
(n, N/A)
Estriol
0.005%
(n, N/A)
Relative
proportion
(95% CI)
Placebo
(n ¼ 226)
60mg
ospemifene
(n ¼ 235)
Relative
proportion
(95% CI)
Placebo
(n ¼ 365)
60mg
ospemifene
(n ¼ 370)
Relative
proportion
(95% CI)
Vaginal dryness
improvement, n (%)
N/A (66.7) N/A (88.2) 1.32 (1.08–1.62),
p¼ 0.001
119 (52.7) 173 (73.6) 1.40 (1.21–1.62),
p< 0.001)
240 (58.7) 312 (76.3) 1.30 (1.18–1.43),
p< 0.001
Dyspareunia
improvement, n (%)
N/A (75.0) N/A (86.5) 1.15 (0.96–1.39),
p¼ 0.095
113 (64.6) 139 (77.7) 1.20 (1.05–1.38),
p¼ 0.007
251 (68.8) 303 (81.9) 1.19 (1.09–1.30),
p< 0.001
N/A, not available
Vagifem 10 µg (Bachmann et al 2008)
Absolute treatment difference (% change with vaginal pH <5)
Ospemifene 60 mg (Study 50310)
Ospemifene 60 mg (Study 50718)
 Ospemifene 60 mg (Study 50821, dryness stratum)
Ospemifene 60 mg (Study 50821, dyspareunia stratum)
0 10
(a)
(b)
(c)
20 30 40 50
Vagifem 10 µg (Simon et al 2008)
Absolute treatment difference (% change with vaginal pH<5.5)
Ospemifene 60 mg (Study 50310)
Ospemifene 60 mg (Study 50718)
 Ospemifene 60 mg (Study 50821, dryness stratum)
Ospemifene 60 mg (Study 50821, dyspareunia stratum)
20 30 40 50 60 70
0.005% oestriol gel (Cano et al 2012)
0.03 mg oestriol (Griesser et al 2012)
0.2 mg oestriol (Griesser et al 2012)
Ospemifene 60 mg (Study 50310)
Ospemifene 60 mg (Study 50718)
 Ospemifene 60 mg (Study 50821, dryness stratum)
Ospemifene 60 mg (Study 50821, dyspareunia stratum)
−1.2−1.4 −1 −0.8 −0.6 −0.4 −0.2 0
Figure 2. Difference between active arm and placebo in (a) percentage of women with vaginal pH <5, (b) pH <5.5, and (c) mean change (observed data only) at
week 12. Data are mean and 95% confidence interval.
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were greater than that observed with 10 lg 17b-estradiol
relative to placebo. In the two estriol studies, we found that
placebo-subtracted mean changes from baseline pH with an
estriol pessary or estriol gel were comparable to those
observed with ospemifene. MV improvements relative to pla-
cebo were similar or greater after 12 weeks for 60mg ospe-
mifene vs. 10 lg 17b-estradiol and vs. estriol pessary/gel.
These data suggest that the non-estrogen, ospemifene, is at
least as effective as local estrogens in the management of
postmenopausal women with VVA symptoms. All treatments
included in the analyses were generally well tolerated, with
comparable tolerability/safety profiles. The safety of ospemi-
fene compared with local estrogens over 1 year appeared to
be comparable in terms of endometrial histology, breast
changes, vaginal discharge, and vaginal candidiasis. With the
exception of one report of endometrial cancer that was pos-
sibly related to 10 lg 17b-estradiol, there was no evidence of
an increased risk of cancer, including breast cancer.
The uncertainty around the risk of thrombosis also
appeared to be no different to that with local estrogens.
Unfortunately, only the 52-week placebo-controlled study
with 10 lg 17b-estradiol14 was suitable for a comprehensive
comparison of AEs – the majority of published local estrogen
studies either did not report AEs or reported AEs very select-
ively. Based on the available data, the incidence of headache
compared with placebo was not increased with ospemifene,
whereas it was with 10 lg 17b-estradiol, which confirms
systemic absorption. The incidence of vaginal candidiasis
was not different between ospemifene and 10 lg 17b-
estradiol.
Vagifem 10 µg (Bachmann et al 2008)
(a)
(b)
Vagifem 10 µg (Simon et al 2008)
Ospemifene 60 mg (Study 50718)
 Ospemifene 60 mg (Study 50821, dryness stratum)
 Ospemifene 60 mg (Study 50310)
Ospemifene 60 mg (Study 50821, dyspareunia stratum)
0
0.2 mg oestriol gel (Griesser et al 2012)
Treatment difference (change from baseline in MV)
0.03 mg oestriol gel (Griesser et al 2012)
Ospemifene 60 mg (Study 50718)
 Ospemifene 60 mg (Study 50821, dryness stratum)
 Ospemifene 60 mg (Study 50310)
Ospemifene 60 mg (Study 50821, dyspareunia stratum)
−5 5 10 15 20 25 30 35 40
0−5 5 10 15 20 25 30 35 40
Figure 3. Difference between active arm and placebo in maturation value (MV) for ospemifene compared with 10 lg 17b-estradiol and estriol. (a) Last case carried
forward, (b) observed cases. Data are mean and 95% confidence interval.
Table 5. Change in endometrial thickness. Data are given as mean ± standard deviation.
Ospemifene trialsa Simon et al. 201026
Naessen & Rodriguez-Bias
200222 Weisberg et al. 200523
Placebo Ospemifene 60mg Placebo 10 lg 17b-estradiol Untreated Estring Estring 25 lg 17b-estradiol
Baseline
Number of women 565 847 103 539 27 27 126 59
Endometrial thickness (mm) 2.2 ± 0.8 2.1 ± 0.8 2.2 ± 0.9 2.1 ± 0.9 1.4 ± 1.1 1.1 ± 0.8 2.5 2.6
52 weeks (LOCF) (LOCF) (48 weeks) (48 weeks)
Number of women 85 345 81 498
Endometrial thickness (mm) 2.1 ± 1.0 2.8 ± 1.4 2.2 ± 1.3 2.2 ± 1.3 2.6 2.7
Change from baseline
Number of women 85 344 81 496 27 27
Endometrial thickness (mm) 0.07 ± 1.23 0.81 ± 1.54 0.09 ± 1.35 0.04 ± 1.24 0.18 0.14 0 0.07
95% Confidence interval 0.52–0.16 0.35–0.07
p-value between-group testb 0.0001 0.654 0.54 0.81
a, Includes studies reported by Simon et al. 201329 and Goldstein et al. 201418; b, ospemifene p-value calculated post hoc
LOCF, last observation carried forward
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As noted with other SERMs, the incidence of muscle
spasm was higher with 60mg ospemifene than with placebo
and was not reported in the local estrogen publications. The
majority of muscle spasms observed in the ospemifene phase
2/3 study program were reported as mild or moderate leg
cramps.
Although the methods used in these analyses were as
rigorous as possible, this indirect historical comparison does
have limitations. The number of studies included in the ana-
lysis was small, particularly for efficacy vs. local estrogens. This
was expected given the length of time that the products have
been on the market in Europe – older studies are rarely of a
standard consistent with that needed for a current license
submission (in terms of trial design, endpoints, size, level of
detail, etc.). Furthermore, there were some differences in study
designs and baseline characteristics between studies. For
example, lubricant was provided to women in both the ospe-
mifene and placebo arms in the ospemifene studies (a specifi-
cation of the FDA), thus reducing discomfort due to mild
dryness, but does not appear to have been given in the local
estrogen studies. Finally, MVs at baseline varied across studies
– high baseline MV reduces the amount of improvement that
can be made, compared with a lower baseline MV, so the
results should be interpreted with caution.
The results of this indirect comparison suggest that the
magnitude of the clinical effect observed with ospemifene is
comparable to, or better than, that seen with local vaginal
estrogens. The safety/tolerability profiles of ospemifene and
local vaginal estrogens appear to be similar. The analysis sug-
gests that, for ospemifene indicated in postmenopausal
women with VVA who are not candidates for local estrogens,
similar efficacy to that observed with local vaginal estrogens
can be expected, with a comparable, but slightly different
safety profile. Most local estrogens are recommended in the
lowest dose for the shortest duration possible. However,
ospemifene can be used as long as the benefit outweighs
the risk, subject to careful appraisal that is undertaken at
least annually.
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